Cite
Duska LR, Filiaci VL, Walker JL, et al. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021;27(10):2734-2741doi: 10.1158/1078-0432.CCR-20-4618.
Duska, L. R., Filiaci, V. L., Walker, J. L., Holman, L. L., Hill, E. K., Moore, R. G., Ring, K. L., Pearl, M. L., Muller, C. Y., Kushnir, C. L., Lankes, H. A., Samuelson, M. I., Carrick, K. S., Rajan, A., Rodgers, W. H., Kohn, E. C., Piekarz, R., & Leslie, K. K. (2021). A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2734-2741. https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska, Linda R, et al. "A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2734-2741. doi: https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25. PMID: 33766814; PMCID: PMC8127359.
Copy
Download .nbib
